文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

转甲状腺素蛋白心脏淀粉样变治疗改善重度主动脉瓣狭窄换瓣术后结局

Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.
PubMed 文献 · Eur Heart J · 2025-01-01

本研究为多中心国际注册研究,纳入226例主动脉瓣狭窄合并转甲状腺素蛋白心脏淀粉样变患者,发现ATTR特异性药物治疗与较低的全因死亡和心血管死亡独立相关,主动脉瓣置换亦改善生存,两者联合预后最佳。

要点

  • ATTR特异性药物与全因死亡(加权HR 0.40,95%CI 0.24-0.68)和心血管死亡(加权HR 0.47,95%CI 0.27-0.83)降低独立相关。
  • 主动脉瓣置换改善总队列生存(HR 0.60,95%CI 0.39-0.93)及重度AS亚组生存(HR 0.42,95%CI 0.26-0.70)。
  • 同时接受ATTR特异性药物和主动脉瓣置换的患者预后最佳,与单纯AS换瓣对照队列相当。

核心结论

  • ATTR特异性治疗和主动脉瓣置换均对主动脉瓣狭窄合并ATTR心脏淀粉样变患者带来显著生存获益。
  • 结果需在非随机研究设置和患者特征差异的背景下解读。

研究设计与样本

  • 多中心、国际、跨大西洋注册研究(ClinicalTrials.gov NCT06129331)。
  • 纳入16个国家10个中心的226例显著主动脉瓣狭窄(中度/重度)合并ATTR心脏淀粉样变患者,年龄85±6岁,80.4%男性。
  • AS严重程度经胸超声心动图诊断,ATTR-CA经骨闪烁显像心肌摄取和/或心内膜活检阳性且无单克隆蛋白诊断。
  • 终点为全因死亡、心血管死亡和心力衰竭住院,与匹配EuroSCORE II的单纯AS接受AVR对照队列比较。

主要发现

  • AS严重程度:重度196例(86.7%),中度30例(13.3%)。
  • 瓣膜治疗策略:经导管/外科AVR 71.7%/3.5%,球囊成形术1.3%,保守治疗23.5%。
  • 中位随访3.6±1.7年,112例(49.6%)死亡(中心血管死亡89例,79.5%),58例(25.7%)发生HHF。
  • ATTR特异性药物与较低全因死亡(加权HR 0.40,95%CI 0.24-0.68)和心血管死亡(加权HR 0.47,95%CI 0.27-0.83)独立相关,但与HHF无关。

临床怎么用

  • 对主动脉瓣狭窄合并ATTR心脏淀粉样变患者,应考虑ATTR特异性药物治疗以降低死亡风险。
  • 主动脉瓣置换可改善生存,与ATTR特异性药物联合可能带来最佳预后。
  • ATTR特异性药物对心力衰竭住院的获益未达统计学显著,需综合管理心衰。

局限性

  • 非随机研究设置,存在患者特征差异和选择偏倚。
  • 接受ATTR特异性药物者更年轻、EuroSCORE II更低、中度AS比例更高,但室间隔更厚和左室功能更差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Concomitant aortic stenosis (AS) and transthyretin-associated cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of structural heart failure. Aortic valve replacement (AVR) improves prognosis in this population, but the efficacy of ATTR-specific medication remains unclear. This study aimed to investigate the prognostic implications of ATTR-specific medication in patients with dual AS-CA. METHODS: This is a multicenter, international, transatlantic registry of patients with a concomitant pathology of significant AS (moderate/severe) and ATTR-CA (ClinicalTrials.gov identifier: NCT06129331). AS severity was diagnosed by transthoracic echocardiography and ATTR-CA by myocardial uptake on bone scintigraphy and/or positive endomyocardial biopsy in the absence of monoclonal proteins. Mortality [all-cause and cardiovascular (CV)] and hospitalisation for heart failure (HHF) served as clinical endpoints. Outcomes were compared with a control cohort of confirmed lone AS receiving AVR matched for EuroSCORE II. RESULTS: Of 226 patients with dual pathology (85 ± 6 years, 80.4% male) identified in 16 centres across 10 countries, AS was severe in 196 (86.7%), and moderate in 30 (13.3%). Valve treatment strategies were transcatheter/surgical AVR in 71.7%/3.5%, balloon angioplasty in 1.3%, and conservative management in 23.5%. Seventy-three patients (32.3%) were prescribed, and 69 patients (30.5%) eventually received ATTR-specific medication (99% tafamidis) and were younger, with lower EuroSCORE II, a higher portion of moderate AS, but higher interventricular septum thickness and more severely impaired left ventricular function compared with patients without ATTR medication. After 3.6 ± 1.7 years, 112 (49.6%) had died [CV death: 89 (79.5%)] and 58 (25.7%) experienced HHF. ATTR-specific medication was independently associated with lower all-cause [weighted hazard ratio (HR) 0.40, 95% confidence interval (CI) 0.24-0.68] and CV mortality (weighted HR 0.47, 95% CI 0.27-0.83) but not HHF. AVR improved survival in the overall (HR 0.60, 95% CI 0.39-0.93) and severe AS cohort (HR 0.42, 95% CI 0.26-0.70). Patients who received both ATTR-specific medication and AVR had the most favourable prognosis, comparable to a control cohort with lone AS undergoing AVR. CONCLUSIONS: ATTR-specific treatment and AVR both result in significant survival benefit in dual pathology AS and ATTR-CA. Results should be interpreted in the context of the non-randomized study setting and differences in patient characteristics.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Nitsche C, Dobner S, Rosenblum HR, et al. Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. Eur Heart J. 2025. PMID: 40452225. doi:10.1093/eurheartj/ehaf362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。